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Chronic pain management 





Problem: high dose oxycodone and XR 
hydromorphone pose serious abuse potential 
and safety risk
 VT has passed new legislation rules regulating prescribing practices to 
minimize the risk of opioid abuse in our communities. “This rule 
provides legal requirements for the appropriate use of opioids in 
treating chronic pain in order to minimize opportunities for misuse, 
abuse, and diversion, and optimize prevention of addiction and 
overdose.”
 Long term use of opiate medication for pain leads to tolerance, 
addiction, abuse, diversion, and adverse effects
 There is dose dependent evidence of increased risk of overdose, abuse 
and dependence, fracture, and myocardial infarction
 Prescribers are responsible for release of these drugs into 
communities but need to be aware of best practices to ensure safety 
to themselves, their patients, and their communities 
Cost considerations 
 Nationally, of the 22,767 deaths relating to 
prescription drug overdose in 2013, 16,235 
(71.3%) involved opioid painkillers. 
Prescription opioid abuse costs were about 
$55.7 billion in 2007
 Vermont’s overdose death rate for 2010 is 
9.7 per 100,000 population, about 60 
deaths/year 
 Street value of oxycodone and hydrocodone 
are somewhere between $1-2 per milligram 
in VT. Therefore, a 30mg daily script has a 
$60 daily or $1680 monthly value. This 
represents incentive for diversion.  
Prescription costs 
Tablets (Oxycodone-Acetaminophen)
2.5-325 mg (100): $204.91
5-325 mg (100): $136.87
7.5-325 mg (100): $271.54
10-325 mg (100): $355.08
Tablets (Percocet)
2.5-325 mg (100): $743.50
5-325 mg (100): $1040.57
7.5-325 mg (100): $1124.22
10-325 mg (100): $1470.01
Tablets (OxyCODONE HCl)
5 mg (100): $54.11
10 mg (100): $62.50
15 mg (100): $189.48
20 mg (100): $110.30
30 mg (100): $358.93
Morrisville Community Cost and Perspectives 
 There are 29 patients in the Morrisville Family Health Care 
practice being treated with chronic high dose opiates that are 
not abuse resistant, accounting for thousands of Percocet and 
Oxycodone pills released into the town and greater community 
(Morrisville, Hyde Park, Eden, Elmore, Hardwick, Stowe and 
more) per month. This represents a street value of $30,000-
$50,000 per month and may contribute to adverse health effects 
and overdose in the community. As a principle source of 
prescription opioids for the region, this practice must be 
responsible and accountable for its prescription practices. 
Interviews with several providers (Kim Bruno, Dave Roy, Phil 
Kiely) and a community coordinator (Jean Audet) provided 
feedback about various aspects of prescription narcotics in the 
region. 
Community perspectives: Prescriber Interviews
 What is your strategy, pharmacological and otherwise, for managing chronic pain?
 Kim Bruno: “I make sure to go through lots of modalities like PT, exercise, mental health management, 
antidepressants, neuromodulators, lidocaine patches, before chronic [opioid] pain meds. Its not perfect because 
not everyone [patients] is willing to do it”
 Dave Roy: “I go through the litany of pain medications, clinics, epidurals. I find clinics are typically useless for 
med management help. Chronic pain groups can help, but I haven’t seen a lot of success with that kind of stuff.” 
 Do the prescribing habits of providers in the practice put the community at risk?
 KB: “We put the community at risk. Some of us prescribe more than others, some are less stern than others. Loosy
goosy habits put the community at risk. We are good about not just blindly refilling and we make patients 
understand their responsibility. If you don’t believe in chronic pain you wont see it because patients will leave 
you. Fundamentally it is a risk we need to take.” 
 DR: “Anyone who prescribes is at risk of causing harm. Don’t believe the patients every time ‘the dog ate the 
pill’. Some people may be pulling the wool over my eyes. The tradeoff is not giving meds to people that really 
need it, which is as bad if not worse. I have been more aggressively monitoring in that last year and have caught a 
few people with random urine screens. VPMS has not helped me to bust anybody.”
 What do you if a narcotics contract is breached?
 KB: “I have had few breaches and I stopped prescribing. Im not afraid to kick them out. For a couple of patients I 
switched to long acting formulations, increased frequency of visits, shortened script duration, pill counts and 
urines”
 DR: “it depends on what happens. I don’t lose a lot of sleep if its positive for marijuana. If I catch something in a 
urine I will confront patients and have had to discontinue patients in the past. I will confirm on dominion. If I 
catch overt diversion I throw them out of practice. But if it’s a legitimate mistake I try to help.”
Interviews continued
 What is your understanding of the research regarding the efficacy of long 
term pain management with narcotics?
 KB: “Its not great research. This approach is not based in great science. These meds 
perpetuate pain rather than treat it over time.”
 DR: “I know that there is evidence that its not that beneficial. I think regardless of 
research there is a subgroup of patients that this medicine just seems to work for. I 
am more judicious about starting patients and increasing dosage now than I used to 
be.”
 How would you feel about using a new standardized template for pain 
management documentation? 
 KB: “I would be all over it”
 DR: “I would have to look at it kind of closely and see. It’s a good way to make sure 
everything is covered but it makes it difficult to think outside the box. I look at 
anything that is rigid as iffy.”
Intervention: form a database of at risk 
patients and assess documentation 
compliance with VT rules
 Methodology
 Practice list obtained of all patients prescribed long term narcotics 
without anti-abuse formulations 
 Patients taking high dose (>30 mg oxycodone or >40mg XR 
hydromorphone) identified from larger group
 Records of each patient were audited for compatibility with new 
VT guidelines for effective monitoring and documentation
 Database created to capture documentation metrics
 Data analyzed to determine rates of compliance with guidelines 
 Evaluation and recommendations for the future made to practice 
Results
Compliance with Rule Governing the Prescribing of Opioids for Chronic Pain
Documentation requirements prior to initiating prescription  Percentage Compliant
Medical and physical evaluation 90%
Diagnoses supporting use of medication 97%
Risks and benefits of medication Incomplete data
Inability to control pain with alternative therapies Incomplete data
Informed consent 79%
Controlled substance treatment agreement 93%
VPMS query documentation 
Review of prior controlled substance prescriptions Incomplete data 
Repeat query every 120 days Has not yet started
Prescription requirements 
Presciption has maximum daily dose 100%
Prescription is for a 30 day maximum 100%
Follow up  visit documentation  requirements
Whether to continue prescribing 86%
Need for substance abuse consultaltion 0%
Provider explanation and patient agreement of consequences of 
agreement violation 7%





 Physicians are performing well in the following areas:
 writing prescriptions with maximum dosage for a maximum of 30 days (100%)
 Documentation of diagnosis (97%)
 routine follow up visits (93%)
 Controlled substance agreement documentation (93%)
 Physicians need improvement in the following areas of documentation:
 Informed consent (79%)
 Explanation of consequences of failure to adhere to contract (7%)
 Whether there is need for substance abuse counselling (0%)
 Limitations
 Data for patients who have been on these medications since before EMR records 
were in use or were initiated by physicians from other practices was often 
incomplete 
 It is difficult to measure the effect of prescribing practices and drug abuse with a 
small sample size in a small community 
 According to interviews, physicians have different opinions about whether a 
standardized template would be acceptable within their practices 
Future recommendations 
1) A chronic opioid for pain management template should be developed that is used for each initial 
patient visit. This should include:
 Diagnosis requiring pain management with high dose opioid: _________
 Risks and benefits of medication discussed? Yes/No
 Non opioid treatment options are ineffective, not tolerated, or inadequate? Yes/No
2) A chronic opioid for pain management template should be developed that is used for each follow up 
visit. This should include:
 Continuation of high dose opioid prescription? Yes/No
 Patient was made aware of consequences of failure to adhere to controlled substance agreement? Yes/No
 Substance abuse services recommended? Yes/No
3) An EHR alert should be created to notify physicians when a patient that is missing an informed 
consent or narcotics contract comes in for an office visit
4) This audit should be repeated in 1 year to measure improvement in documentation 
Improvement in the documentation process will remind physicians to address important issues that 
they may not be talking about now. Because this patient population is at high risk for medication 
abuse and adverse effects, safety will be improved by making these improvements. Furthermore, the 
community at large will be safer because responsible medication use is more likely to prevent 
diversion. 
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